Biogen Inc. announced its long-awaited gene therapy collaboration, with Genovo Inc, a one-person startup associated with James Wilson, director of the Institute for Human Gene Therapy at the University of Pennsylvania.

BGEN (Cambridge, Mass.) will invest more than $35 million in Genovo over five years, including an undisclosed equity interest and milestone payments. BGEN received exclusive worldwide rights to certain gene therapy products, including products for cystic fibrosis and familial hypercholesterolemia (FH) and up to 20 additional products targeting diseases of the liver and lung. Genovo will receive a royalty on sales.